View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on Actinium Pharma (ATNM)
-
Actinium Pharma (ATNM) Appoints June Almenoff to its Board
-
Actinium Pharma (ATNM) Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
-
Actinium Pharma (ATNM) PT Lowered to $4 at H.C. Wainwright
-
Actinium Pharma (ATNM) PT Lowered to $9 at Jones Trading
-
Actinium Pharma (ATNM) Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients
-
Actinium Pharma (ATNM) Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development
